Felix Ehret1,2, Markus Kufeld2, Christoph Fürweger2, Alfred Haidenberger2, Paul Windisch2,3, Susanne Fichte4, Ralph Lehrke5, Carolin Senger1,6, David Kaul1,7, Daniel Rueß8, Maximilian Ruge8, Christian Schichor9, Jörg-Christian Tonn9, Günter Stalla10,11, Alexander Muacevic2. 1. Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, 13353 Berlin, Germany. 2. European Cyberknife Center, 81377 Munich, Germany. 3. Department of Radiation Oncology, Kantonsspital Winterthur, 8400 Winterthur, Switzerland. 4. CyberKnife Center Mitteldeutschland, 99089 Erfurt, Germany. 5. German CyberKnife Center, 59494 Soest, Germany. 6. Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité CyberKnife Center, 13353 Berlin, Germany. 7. German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. 8. Department of Stereotaxy and Functional Neurosurgery, Center for Neurosurgery, University Hospital Cologne, 50937 Cologne, Germany. 9. Department of Neurosurgery, Ludwig-Maximilians-University Munich, 81377 Munich, Germany. 10. Medicover Neuroendocrinology, 81667 Munich, Germany. 11. Department of Medicine IV, Ludwig-Maximilians-University Munich, 81377 Munich, Germany.
Abstract
BACKGROUND: The rates of incomplete surgical resection for pituitary macroadenomas with cavernous sinus invasion are high. In growth hormone-producing adenomas, there is a considerable risk for persistent acromegaly. Thus, effective treatment options are needed to limit patient morbidity and mortality. This multicenter study assesses the efficacy and safety of robotic radiosurgery (RRS) for patients with cavernous sinus-invading adenomas with persistent acromegaly. METHODS: Patients who underwent RRS with CyberKnife for postoperative acromegaly were eligible. RESULTS: Fifty patients were included. At a median follow-up of 57 months, the local control was 100%. The pretreatment insulin-like growth factor 1 (IGF-1) levels and indexes were 381 ng/mL and 1.49, respectively. The median dose and prescription isodose were 18 Gy and 70%, respectively. Six months after RRS, and at the last follow-up, the IGF-1 levels and indexes were 277 ng/mL and 1.14, as well as 196 ng/mL and 0.83, respectively (p = 0.0001 and p = 0.0002). The IGF-1 index was a predictor for biochemical remission (p = 0.04). Nine patients achieved biochemical remission and 24 patients showed biochemical disease control. Three patients developed a new hypopituitarism. CONCLUSIONS: RRS is an effective treatment for this challenging patient population. IGF-1 levels are decreasing after treatment and most patients experience biochemical disease control or remission.
BACKGROUND: The rates of incomplete surgical resection for pituitary macroadenomas with cavernous sinus invasion are high. In growth hormone-producing adenomas, there is a considerable risk for persistent acromegaly. Thus, effective treatment options are needed to limit patient morbidity and mortality. This multicenter study assesses the efficacy and safety of robotic radiosurgery (RRS) for patients with cavernous sinus-invading adenomas with persistent acromegaly. METHODS:Patients who underwent RRS with CyberKnife for postoperative acromegaly were eligible. RESULTS: Fifty patients were included. At a median follow-up of 57 months, the local control was 100%. The pretreatment insulin-like growth factor 1 (IGF-1) levels and indexes were 381 ng/mL and 1.49, respectively. The median dose and prescription isodose were 18 Gy and 70%, respectively. Six months after RRS, and at the last follow-up, the IGF-1 levels and indexes were 277 ng/mL and 1.14, as well as 196 ng/mL and 0.83, respectively (p = 0.0001 and p = 0.0002). The IGF-1 index was a predictor for biochemical remission (p = 0.04). Nine patients achieved biochemical remission and 24 patients showed biochemical disease control. Three patients developed a new hypopituitarism. CONCLUSIONS: RRS is an effective treatment for this challenging patient population. IGF-1 levels are decreasing after treatment and most patients experience biochemical disease control or remission.
Authors: Paul Leach; Ahmed H Abou-Zeid; Tara Kearney; Julian Davis; Peter J Trainer; Kanna K Gnanalingham Journal: Neurosurgery Date: 2010-11 Impact factor: 4.654
Authors: David M Cook; Kevin C J Yuen; Beverly M K Biller; Stephen F Kemp; Mary Lee Vance Journal: Endocr Pract Date: 2009 Sep-Oct Impact factor: 3.443
Authors: A M Landolt; D Haller; N Lomax; S Scheib; O Schubiger; J Siegfried; G Wellis Journal: J Clin Endocrinol Metab Date: 2000-03 Impact factor: 5.958
Authors: Christopher S Graffeo; Diane Donegan; Dana Erickson; Paul D Brown; Avital Perry; Michael J Link; William F Young; Bruce E Pollock Journal: Neurosurgery Date: 2020-09-01 Impact factor: 5.315